$ACAD management preparing for the #buyout by $PFE $AZN #CEO gets stock option for 243,750 shares exercisable at $35.80 (will vest on b/o)
After all the recent good news, I expect AZN would be back on the radar as a takeover target. I wouldn't be surprised to see offers in the $45 to $50 range. AZN is a dangerous stock to short with the dividend and with the potential for a buyout.
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 4,338 NYSE Stocks Price Analysis This stock mode of correlation coefficient is 0.8 In other words, the correlation coefficient of the other stocks
Breakout of 3400% with $KOSK on vending product Launch for the pharmaceutical and medical companies. Announcement soon.
FDA APPROVED ADMS
Things seem to be getting overextended for AZN. I started receiving notifications from awe-some*sto-cks the other week and so far they have presented interesting new trade ideas.
Do you think this thing is done selling? Showing us a buy signal now on AZN? Im not sure about you guys but awe-some*sto-ck*s has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
Fundamental growth and profitability are looking good. Higher rating at stockFA. Expected to pick up momentum.
Al on CC
What happened to Dividend? It was 1.90 a few days ago. Now .90. This site is very inaccurate.
No More Pricks – Quick Dissolvable Tablet is Set to Disrupt the Vaccine Industry
The quest to improve vaccination efforts in developing nations may yield huge side benefits to the industrialized world; an end to needle injections.
AZN's drop has made it more attractive as a buyout play. Next week's dividend is another positive reason to be buying in here. Just saw an article saying PFE's less than stellar earnings show a need to do a deal. If not PFE, could be another large pharma come a knockin'.
AZN should give us a bit of a pop today.
Hey Hey Hey
For as much as I want a buyout, I don't think it will happen with Soriot and the current board. Soriot has to go before he destroys anymore shareholder value. The media has to stop to referring to the PFE offer #$%$ GBP/share, that minimizes the damage Soriot has already inflicted on the shareholders including that homer Woodford. The PFE offer was $116-$120 Billion. Soriot cost the shareholders $45+ Billion dollars. None of the promises from his forked tongue will come to fruition. All we can hope for is if an activist shareholder can force the company to put itself up for sale.. I can't believe any of the large shareholders can just sit passively as Soriot continues to sell off the family jewels to hit his bonus.
Benralizumab has an FDA action date during Q4 2017 and AstraZeneca are preparing to launch in the US in the beginning of 2018 .
Up almost 1% in pre-market. Looks like buyers are coming back and paying up. Any speculation of a possible deal will make this baby pop, and that appears to be behind the buying interest.
Looks like $30 is the new base. Once speculation starts about who might have an interest in buying AZN, I expect the stock will move up a couple of bucks. The upcoming generous dividend makes it easy to hold and wait, especially if you bought on the recent drop.